LONDON - Domantis Ltd. sealed a multiproduct deal with Bristol-Myers Squibb Co. for its domain antibodies (dAb) worth $9.2 million in up-front and research payments, plus $20 million per dAb in preclinical and clinical milestones, plus royalties on sales. The aim is to discover and develop dAbs against T-cell co-stimulation targets that cannot be hit by conventional antibodies. (BioWorld Today)